In addition, MLNK extracted from the peripheral blood were modified to express an anti-CD19 CAR (CD19-CAR-ML), which displayed significantly increased IFN-γ production, degranulation, and improved specific responses against their autologous lymphomas compared with non-specific control CAR-MLNK or conventional non-ML CAR-NK cells [116]. The gene discussed is CD19; the disease is lymphoma.